ProKidney Corp. (NasdaqCM: PROK)
Health Care · Biotechnology · US
$1.73
+7.45% today · -31.5% 1Y
ProKidney Corp. (NasdaqCM: PROK) operates in the Biotechnology industry within the Health Care sector. The company is valued at $336.37M and employs 231 people.
Over the last twelve months the share price has lost 31.5%, trading between 1.30 and 3.48.
Tweenvest scores ProKidney Corp. across four factors: quality 31/100, value 55/100. Its strongest factor is value.
PROK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $336.37M
- Revenue (TTM)
- $818.00K
- P/E
- —
- EPS
- -0.56
- Dividend yield
- —
- Beta (5Y)
- 1.72
- 52-week high
- $3.48
- 52-week low
- $1.30
- Avg volume (3M)
- —
- Shares outstanding
- 208.93M
- Employees
- 231
- Next earnings
- —
About ProKidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
- ISIN
- US74291D1046
- Founded
- 2015
- Listed since
- Jun 30, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.